Terms: = Skin cancer AND BCL2, Bcl-2, 596, ENSG00000171791 AND Prognosis
160 results:
1. The Level of Agreement between Self-Assessments and Examiner Assessments of Melanocytic Nevus Counts: Findings from an Evaluation of 4548 Double Assessments.
Gefeller O; Kaiser I; Brockmann EM; Uter W; Pfahlberg AB
Curr Oncol; 2024 Apr; 31(4):2221-2232. PubMed ID: 38668067
[TBL] [Abstract] [Full Text] [Related]
2. Effective Targeting of Melanoma Cells by Combination of Mcl-1 and bcl-2/Bcl-x
Peng Z; Gillissen B; Richter A; Sinnberg T; Schlaak MS; Eberle J
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542429
[TBL] [Abstract] [Full Text] [Related]
3. Study on the mechanism of S100A4-mediated cancer oncogenesis in uveal melanoma cells through the integration of bioinformatics and in vitro experiments.
Chen H; Zhang W; Shi J; Tang Y; Chen X; Li J; Yao X
Gene; 2024 Jun; 911():148333. PubMed ID: 38431233
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic Significance of Tumor-Infiltrating Lymphocytes and High-Risk Human Papillomavirus in Ocular Sebaceous Carcinoma: A Comprehensive Analysis.
Jeong SU; Song JS; Lee HJ; Sa HS; Cho KJ
Mod Pathol; 2024 Apr; 37(4):100449. PubMed ID: 38369185
[TBL] [Abstract] [Full Text] [Related]
5. Sinonasal DLBCL: molecular profiling identifies subtypes with distinctive prognosis and targetable genetic features.
Eriksen PRG; de Groot F; Clasen-Linde E; de Nully Brown P; de Groen R; Melchior LC; Maier AD; Minderman M; Vermaat JSP; von Buchwald C; Pals ST; Heegaard S
Blood Adv; 2024 Apr; 8(8):1946-1957. PubMed ID: 38324724
[TBL] [Abstract] [Full Text] [Related]
6. PD-1 blockade combined with decitabine to treat refractory peripheral T-cell lymphoma not otherwise specified: A case report and review of literature.
Han X; Liu X; Zhang C; Wen Q; Zhang X
J Cancer Res Ther; 2023 Dec; 19(6):1680-1684. PubMed ID: 38156938
[TBL] [Abstract] [Full Text] [Related]
7. Evaluation of Ki67, Bax, bcl-2 and KIT in canine cutaneous mast cell tumours and their relationship with histopathology and prognosis.
Aytemiz Danyer I; Gürel A
Acta Vet Hung; 2024 Jan; 71(3-4):183-192. PubMed ID: 38112689
[TBL] [Abstract] [Full Text] [Related]
8. The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis.
Tonozuka Y; Tanaka H; Nomura K; Sakaguchi K; Soeda J; Kakimoto Y
Cancer Chemother Pharmacol; 2024 Feb; 93(2):137-149. PubMed ID: 37921901
[TBL] [Abstract] [Full Text] [Related]
9. Circulating Tumor DNA: A Promising Biomarker for Predicting Recurrence in Patients with BRAF-Negative Melanoma.
Aoude LG; Brosda S; Ng J; Lonie JM; Belle CJ; Patel K; Koufariotis LT; Wood S; Atkinson V; Smithers BM; Pearson JV; Waddell N; Barbour AP; Bonazzi VF
J Mol Diagn; 2023 Oct; 25(10):771-781. PubMed ID: 37544359
[TBL] [Abstract] [Full Text] [Related]
10. Clinicopathological, cytogenetic, and molecular profiles of primary cutaneous diffuse large B-cell lymphomas.
Uccella S; Goteri G; Maiorana A; Donati V; Tibiletti MG; Magnoli F; Facchi S; Merchiori D; Morsia E; Papotti R; Bettelli S; Forti E; Galimberti S; Rupoli S; Filosa A; Dardanis D; Bomben R; Braglia L; Pozzi S; Sacchi S
Hum Pathol; 2023 Jun; 136():44-55. PubMed ID: 36997030
[TBL] [Abstract] [Full Text] [Related]
11. Random skin Biopsy for Diagnosis of Intravascular Large B-Cell Lymphoma: A Case Report and Literature Review.
Lv Y; Xu L; Liu X; Wang Y
Am J Dermatopathol; 2023 May; 45(5):320-322. PubMed ID: 36939136
[TBL] [Abstract] [Full Text] [Related]
12. Clinical features and factors affecting prognosis and partial deterioration of ocular papilloma: a retrospective study of 298 cases.
Jian H; He W
Graefes Arch Clin Exp Ophthalmol; 2023 Aug; 261(8):2395-2402. PubMed ID: 36933010
[TBL] [Abstract] [Full Text] [Related]
13. Locally advanced choroidal melanoma with favorable molecular prognosis - case report.
Bălăşoiu AT; Ştefănescu-Dima AŞ; Bălăşoiu M; Ciurea RN; Muraru A; Dan AO; Simionescu CE
Rom J Morphol Embryol; 2022; 63(4):645-652. PubMed ID: 36808200
[TBL] [Abstract] [Full Text] [Related]
14. Survival Mechanisms of Metastatic Melanoma Cells: The Link between Glucocorticoids and the Nrf2-Dependent Antioxidant Defense System.
Obrador E; Salvador-Palmer R; López-Blanch R; Oriol-Caballo M; Moreno-Murciano P; Estrela JM
Cells; 2023 Jan; 12(3):. PubMed ID: 36766760
[TBL] [Abstract] [Full Text] [Related]
15. [Clinical Characteristics and Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm].
Zhang XL; Liu B; Li N; Li LK; Ji XJ; Zhou XF; Wang MF; Xu HL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):254-260. PubMed ID: 36765508
[TBL] [Abstract] [Full Text] [Related]
16. Silencing of SiX-4 enhances the chemosensitivity of melanoma cells to Cisplatin.
Vazirabad AF; Noorolyai S; Baghbani E; Mahboob S; Zargari F; Rahmani S; Sorkhabi A; Montazami N; Sameti P; Baradaran B
Pathol Res Pract; 2022 Dec; 240():154194. PubMed ID: 36370483
[TBL] [Abstract] [Full Text] [Related]
17. Venetoclax-induced vitiligo in a patient with chronic lymphocytic leukemia.
Abdeen M; Vusqa UT; Asawa P; Felton K; Rinchuse D; Khan C; Samhouri Y; Lister J
Anticancer Drugs; 2022 Nov; 33(10):1167-1170. PubMed ID: 36255070
[TBL] [Abstract] [Full Text] [Related]
18. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics.
Adimora IJ; Wilson NR; Pemmaraju N
Cancer; 2022 Aug; 128(16):3019-3026. PubMed ID: 35726525
[TBL] [Abstract] [Full Text] [Related]
19. Plasmablastic myeloma in Taiwan frequently presents with extramedullary and extranodal mass mimicking plasmablastic lymphoma.
Chen BJ; Yuan CT; Yang CF; Ho CH; Lin YK; Su YZ; Chou HC; Chuang SS
Virchows Arch; 2022 Aug; 481(2):283-293. PubMed ID: 35657404
[TBL] [Abstract] [Full Text] [Related]
20. Alantolactone Inhibits Melanoma Cell Culture Viability and Migration and Promotes Apoptosis by Inhibiting Wnt/β-Catenin Signaling.
Zhang L; Chen J; Chen Y; Zou D; Pu Y; Wei M; Huang Y; Li Y; Huang Q; Chen J
Anticancer Agents Med Chem; 2023; 23(1):94-104. PubMed ID: 35598249
[TBL] [Abstract] [Full Text] [Related]
[Next]
